Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
NCT03856216 · M.D. Anderson Cancer Center · PHASE2 · terminated · last registry update 2026-04-15 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “\<75% participation” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF3R in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-29Also stopped (suspended): University of Washington, Asparaginase Erwinia chrysanthemi + Cyclophosphamide (NCT06738368)
- 2026-05-26Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cyclosporine + Mycophenolate Mofetil (NCT03434730)
- 2026-05-07Also stopped (withdrawn): M.D. Anderson Cancer Center, Fludarabine + Cytarabine (NCT07428486)
- 2026-04-21Phase 3 first posted: Fujian Medical University Union Hospital, PD-1 Inhibitors (NCT07541755)
- 2026-03-04Results posted on the registry: St. Jude Children's Research Hospital, Cyclophosphamide + Fludarabine (NCT03849651)
- 2026-02-24Also stopped (withdrawn): Ossium Health, Inc., Cyclophosphamide + Fludarabine (NCT05170828)
- 2025-09-09Also stopped (terminated): Sanofi, Isatuximab + Dexamethasone or equivalent (NCT03860844)
- 2025-08-26Results posted on the registry: Masonic Cancer Center, University of Minnesota, filgrastim + busulfan (NCT00357565)
- 2025-08-11Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT05032183)
- 2025-08-11Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT05032183)
- 2025-08-06Results posted on the registry: Center for International Blood and Marrow Transplant Research, Fludarabine + Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5 (NCT02793544)
- 2025-05-23Results posted on the registry: M.D. Anderson Cancer Center, DS-1594b + Azacitidine (NCT04752163)
- 2025-05-23Also stopped (terminated): M.D. Anderson Cancer Center, DS-1594b + Azacitidine (NCT04752163)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision